The Intersection of Generative AI and De Novo Protein Design How is computational modeling reducing R&D lead times?
The traditional trial-and-error approach to protein modification is rapidly being superseded by generative AI models. In 2024, the ability to predict protein folding and stability with near-atomic accuracy has allowed biopharma companies to bypass months of wet-lab screening. This computational shift is fundamental to maintaining a...